Introduction
'Does sex matter in glaucoma?' A thought-provoking editorial piece by Higginbotham in 2004 [1] provides an excellent overview of gender and glaucoma. The author presented a line of evidence supporting that sex does matter in glaucoma. First, the Rotterdam study demonstrated increased risk of primary open angle glaucoma (POAG) in women with early menopause [2] . Second, women are at higher risk for primary angle closure glaucoma (PACG) probably due to anatomical predisposition [3,4,5 ,6] . Third, female sex was found to be a risk factor in normal tension glaucoma [7] . Lastly, the changes in the level of female sex hormones may influence intraocular pressure (IOP) as well as vascular resistance that might affect the optic nerve head circulation. As women go through cycles of hormonal changes, this situation might potentially influence the onset and the course of the disease [1] . Accordingly, gender and/or changes in sex hormone levels should be taken into consideration in the care of patients with glaucoma.
It is estimated that glaucoma cases worldwide will increase from 60 million in 2010 to 80 million in 2020 due to increased aging population [6] . Women bear a larger burden than men because not only do women outlive men, but women also outnumber men and represent 60% of all glaucoma cases combined [6] (http://www.cdc.gov/nchs/data/hus/hus08.pdf#026; https://www.cia.gov/library/publications/the-world-fact book/fields/2018.html). As such, awareness of the gender differences might increase attention toward populations at risk. This article provides a comprehensive review of the following topics: gender predilection for glaucoma; gender difference in visual impairment due to glaucoma; the potential protective effect of female sex hormones on glaucoma; and gender disparity in glaucoma.
Previous studies demonstrated that women are at higher risk for PACG (Table 1) [8] [9] [10] [11] [12] [13] [14] [15] [16] . In addition, the risk is particularly high among Asian and Alaskan Native populations [6, [8] [9] [10] [11] [12] . In contrast, there is no clear consensus on gender predilection for POAG (Table 2 ) [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . In whites, the Baltimore Eye Survey and the Beaver Dam Eye study showed no difference in prevalence by sex [13, 14] . In contrast, the Framingham Eye study and the Rotterdam study showed an increased prevalence among men, whereas the Blue Mountains Eye study showed an increased prevalence among women [15, 17, 18] . In contrast, 5-year incidence rates were nonsignificantly higher in women compared with men in the Rotterdam study, which exclusively included white patients [odds ratio (OR): 1.3; 95% confidence interval (CI) 0.9-2.0] [19] . In blacks, the risk appears higher in men [13, 20, 21] . For instance, the Barbados Eye study showed ageadjusted prevalence ratio of 1.4 in men. In Hispanics, the Proyector VER showed no gender difference, whereas the Los Angeles Latino Eye study suggested 1.73 times risk in men (OR: 1.73; 95% CI 1.30-2.30) [16, 22, 23] .
These inconsistencies among population-based studies may result from an inadequacy in the study power necessary to answer this question [24] . In addition, results may be influenced by different criteria and different populations. Based on a Bayesian meta-analysis, Rudnicka et al. [24] determined variation in POAG prevalence with age, gender, race, year of publication and survey methods. The authors demonstrated that blacks had the highest POAG prevalence at all ages, but whites had the steepest increase in the POAG prevalence with age. Based on 61 267 participants from 25 studies, POAG prevalence among men was higher than in women [OR: 1.37; 95% credible interval (CrI) 1.22-1.53]. In contrast, the Eye Diseases Prevalence Research Group did not find any significant gender difference in the POAG prevalence by race [25] . Rudnicka et al. [24] noted that the two meta-analyses used different database, and Friedman et al. [25] had access to unpublished data on gender difference, which allowed them to include additional information that was not available in original studies. In addition, Rudnicka et al. [24] included additional studies from outside USA for the black populations in their meta-analysis. After combining the two meta-analyses, Rudnicka et al. [24] found that the OR was changed to 1.23 (95% CrI 1.06-1.42) and men still had higher risk for POAG compared with women.
In summary, women are at risk for PACG, but the gender predilection for POAG is unclear. Based on the largest meta-analysis, the age-adjusted prevalence of POAG might be higher in men, especially more evident in blacks.
Gender difference in glaucoma blindness: who is at risk for glaucoma blindness? [26 ] .
Apart from the NHIS report, there was little data from the population-based studies that addressed gender difference in glaucoma blindness. For example, age-adjusted odds ratio for monocular blindness due to glaucoma was higher in the US Hispanic women (OR: 1.73; 95% CI 0.47-6.39); however, this was based on a small number of cases [27] . Most studies presented overall (noncausespecific) prevalence of visual impairment and blindness. For example, a report from the World Health Organization and other reports suggest that the risk for visual impairment for all causes is twice as high in women than men in every region of the world [6,26 ,28,29] . Of all causes of blindness, glaucoma is the second leading cause, accounting for 12% of cases of blindness in the world. In addition to the higher risk, women constitute two-third of the world's population of visually impaired and blind individuals and this number is higher, even after age adjustment [28] (http://www.womenseye health.org/; this website provides an excellent overview of Women's Eye Health). Additionally, the Eye Diseases Prevalence Study Group suggested that the risk for blindness might be different in different ethnicities. In whites, the blindness prevalence was higher in women, though it was not significant after age adjustment. In contrast, a higher age-adjusted prevalence of blindness was found among black men [30] .
Approximately, 10% of POAG and 25% of PACG patients are bilaterally blind [6] . The blindness cases are estimated to be 4.5 million for POAG and 3.9 million for PACG in 2010, rising to 5.9 and 5.3 million in 2020, respectively [6] . Who is at risk for glaucoma blindness? This matter is more complex as risk of blindness might be Retrospective review of a national computerized discharge registry during 10-year period, minimal age not defined.
l Adjusted for age. influenced by multiple factors such as biological predisposition, sociocultural factors, as well as racial and gender disparities. It appears that women have a higher risk for blindness for all causes worldwide. Given the higher number of glaucoma cases and the potential higher risk for glaucoma blindness in women, increased awareness and attention toward the care for glaucoma in this vulnerable group is recommended [6] .
Effect of sex hormones on glaucoma: what have we learned from population-based studies? Table 3 [2,31-33] summarizes results from previous studies investigating the effect of female sex hormones on POAG development. The Rotterdam study, a landmark study, investigated the effect of female sex hormones on glaucoma [2] . Specifically, women who entered menopause before age of 45 had a 2.6-fold increased risk for POAG, compared with those who entered menopause after age of 50. This finding is supported in part by other studies. For instance, the Blue Mountains Eye study suggested that shorter estrogen exposure might be associated with POAG [31] . The authors observed higher risk for glaucoma in women with late menarche and increased parity. In addition, there was a nonsignificant increased risk for glaucoma in women with early menopause (OR: 1.7; 95% CI 0.7-3.8) and with history of shorter exposure of endogenous estrogen (<30 years; OR: 1.8; 95% CI 0.6-5.3). More recently, the Nurses' Health study, a 22-year longitudinal cohort study, investigated the association between female sex hormones and POAG incidence [32] . In this study, Pasquale et al. made a notable observation. Specifically, the authors demonstrated the relationship between lower incidence of POAG in women who reported late menopause, but this association was only statistically significant in a group of women older than 65 years of age (risk ratio: 0.53; 95% CI 0.32-0.89). This observation could perhaps explain conflicting results from the Aravind Comprehensive Eye Survey reporting no significant association between POAG and the female reproductive factors, including the onset of menarche, the onset of menopause and the duration of estrogen exposure [33] . However, as Pasquale et al. commented, the mean age of the Aravind study was more than a decade younger than those of other previous studies with positive associations.
If estrogen protects women from developing glaucoma during the reproductive period, could hormone replacement therapy (HRT) reduce risk for glaucoma in postmenopausal women? Table 4 [2, 31] . In contrast, the Los Angeles Latino Eye study showed no association between sex hormone use and POAG [23] . Of note, these aforementioned studies were not originally designed to answer this particular question and, therefore, data on the type of hormone use, onset and duration of HRT and/or birth control use might not be available for analyses. Later, the Nurses' Health study, a 22-year longitudinal cohort study, evaluated the potential effect of the female sex hormones on the development of POAG [32] . The investigators not only evaluated different types of hormone use, but also looked at the incidence of POAG in women at risk, characterized by IOP elevation greater than 21 mmHg. They found significant risk reduction of POAG in women with ocular hypertension who used a combination of estrogen and progestin and found nonsignificant risk reduction in this group of women who used estrogen only. The effect of HRT and/or sex hormones on glaucoma development/risk reduction is perhaps similar to the risk and benefit of HRT for cardiovascular risk reduction in postmenopausal women [34] . This topic is multifaceted and complex as it depends not only on the type and age of initiation of HRT, but also on individual susceptibility for the particular diseases. Based on the evidence, it is possible that the age-related declines in female sex hormones might place women at greater risk for developing glaucoma; however, there presently is insufficient evidence to support HRT use in glaucoma prevention.
Effect of sex hormones on glaucoma: why might female sex hormones be protective?
Higher IOP was demonstrated after menopause [35] . In addition, a significant 1-4 mmHg IOP reduction has been demonstrated after HRT initiation in both women with and without glaucoma [35] [36] [37] . This observation could be explained by the fact that 17b-estradiol augments the activity of endothelial-based nitric oxide synthase (NOS) and, therefore, could regulate smooth muscle tone and vascular resistance. As receptors are located in the ciliary body and the outflow system, it might potentially influence IOP by regulating both aqueous production and aqueous outflow [35, 38] .
In addition, sex hormones have been shown to affect ocular hemodynamics. As opposed to testosterone, estrogen enhances ocular blood flow [39] . It has been demonstrated that aging and age-related declines in female sex hormones negatively affect ocular blood flow [39, 40] . Even after adjusting for age, postmenopausal women demonstrated lower blood velocity and higher vascular resistance, compared with premenopausal women [39] . In addition, it was suggested HRT could improve ocular blood flow in postmenopausal women. For instance, postmenopausal women with HRT had similar vascular resistance distal to the ophthalmic artery, compared with that of young women [41] . In addition, HRT was shown to reduce vascular resistance in the central retinal artery and posterior ciliary artery [35, 42] . Although to a lesser degree, another study also showed the benefit of HRT on ocular blood flow in postmenopausal women with glaucoma [43] . The results were, however, inconsistent when other investigators compared different groups of postmenopausal women with HRT and without HRT. One report showed lower vascular resistance in women with HRT, but others showed no difference between the two groups [35, 41, 44] .
Furthermore, prior investigations using animal models demonstrated neuroprotective effects of female sex hormones. Specifically, 17b-estradiol prevented retinal ganglion cell (RGC) loss induced by an acute IOP elevation in rats and preserved RGC in DBA/2J, a glaucoma mouse model after oophorectomy [45 ,46] . The neuroprotective effect of 17b-estradiol was thought in part to be mediated through estrogen receptors located in the RGC [45 ,46] .
Lastly, estrogen may be protective, yet hormonal effects are complex as the effects of estrogen on cell type could vary depending on the ratio between a-type and b-type estrogen receptors within the tissue [35] . More recently, the Rotterdam study investigated the association between polymorphism in estrogen receptor genes and POAG risk. They found that estrogen receptor-b polymorphisms, and not estrogen receptor-a polymorphisms, were associated with increased incidence of POAG. Of interest, this association was only significant in men, but not in women [47 ] . Further investigation may provide better understanding of this gender difference in the effect of estrogen.
Gender and glaucoma: is there gender difference and/or disparity?
As stated, women outnumber men in rapid growing aging populations (https://www.cia.gov/library/publications/theworld-factbook/fields/2018.html). In addition, women outnumber men in the total number of cases for glaucoma combined. Although there is no clear evidence of gender predilection in POAG, overall, women are likely to become visually impaired due to glaucoma. There are several factors that could influence this discrepancy. These include biological and nonbiological factors (e.g. socioeconomic, cultural, health beliefs and access to healthcare) [48 ] .
Concerning biological factors (gender difference), women are at risk for PACG, but there is no clear predilection for POAG. Of particular interest, it is possible that female sex hormones might provide some protective effect to the optic nerves. After menopause, women may lose this protective effect and, therefore, their risk for POAG reaches that of men. This observation, interestingly, seems to mimic cardiovascular risks in postmenopausal women [34] .
Concerning nonbiological factors (gender disparity), women in some parts of the world have less access to healthcare [29] . In addition, a review of United Healthcare database suggested that women were 24% less likely to be treated for glaucoma [49] . This observation is consistent with previous studies showing lower treatment rates in the intensive care unit and in cardiovascular diseases for women. Considering all factors, older women are particularly at risk and, therefore, attention should be placed to improve the care for this growing group.
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Conclusion
With growing aging populations and an increase in cases of glaucoma and glaucoma blindness worldwide, older women are particularly at higher risk of glaucoma and glaucoma blindness. Furthermore, women carry a larger burden of glaucoma blindness due to longevity and disadvantages in socioeconomics and/or health beliefs. Of interest, female sex hormones may be protective against glaucoma. As issues surrounding gender disparity are complex, further interdisciplinary research involving investigators who specialize in glaucoma, women's health and health disparities is necessary. Increased awareness and understanding of gender health disparities in glaucoma will lead to better targeting populations at risk and better use of available resources to improve care for our glaucoma patients.
